Role of Post-Treatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients Receiving Definitive Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinomas
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives 18F-fluorodeoxyglucose PET/CT scans can be a useful methodto detect recurrence. However, its role in locally advanced head and neck squamous cell carcinomas(HNSCCs) patients after definitive chemoradiotherapy (CRT) has not yet been determined. The current study was performed to identify the role of therapeutic response evaluation usingPET/CT after definitive CRT. Subjects and Method We conducted a retrospective review of patients with locally advancedHNSCCs, and who have undergone definitive CRT from 2009 to 2017 at a single institution. The patients were divided into two groups according to their responses to the treatment(metabolic complete remission [mCR] group or non-mCR group), assessed by PET/CT scansafter definitive CRT. Results Twenty-eight patients were consecutively enrolled. The most common primary siteof cancer was the oropharynx, followed by the oral cavity, hypopharynx, and nasal cavity. The therapeutic response assessed by PET/CT scans was mCR in 14 patients. The median progression-free survival (PFS) was not reached in the mCR group but was 13.3 months for thenon-mCR group (p=0.001). The median overall survival was significantly longer for the mCRgroup (52.5 months) than for the non-mCR group (15.2 months, p=0.002). A multivariate analysisshowed PET/CT response and high-sensitivity C-reactive protein (hsCRP) as independentprognostic factors for PFS (mCR: p=0.027; hsCRP: p=0.042) and for the overall survival(mCR: p=0.006; hsCRP: p=0.020). Conclusion PET/CT scans after definitive CRT predicted the prognosis in patients with locallyadvanced HNSCCs. CRP was a prognostic factor affecting the outcomes of treatments.
Abstract
Background and Objectives 18F-fluorodeoxyglucose PET/CT scans can be a useful methodto detect recurrence. However, its role in locally advanced head and neck squamous cell carcinomas(HNSCCs) patients after definitive chemoradiotherapy (CRT) has not yet been determined. The current study was performed to identify the role of therapeutic response evaluation usingPET/CT after definitive CRT. Subjects and Method We conducted a retrospective review of patients with locally advancedHNSCCs, and who have undergone definitive CRT from 2009 to 2017 at a single institution. The patients were divided into two groups according to their responses to the treatment(metabolic complete remission [mCR] group or non-mCR group), assessed by PET/CT scansafter definitive CRT. Results Twenty-eight patients were consecutively enrolled. The most common primary siteof cancer was the oropharynx, followed by the oral cavity, hypopharynx, and nasal cavity. The therapeutic response assessed by PET/CT scans was mCR in 14 patients. The median progression-free survival (PFS) was not reached in the mCR group but was 13.3 months for thenon-mCR group (p=0.001). The median overall survival was significantly longer for the mCRgroup (52.5 months) than for the non-mCR group (15.2 months, p=0.002). A multivariate analysisshowed PET/CT response and high-sensitivity C-reactive protein (hsCRP) as independentprognostic factors for PFS (mCR: p=0.027; hsCRP: p=0.042) and for the overall survival(mCR: p=0.006; hsCRP: p=0.020). Conclusion PET/CT scans after definitive CRT predicted the prognosis in patients with locallyadvanced HNSCCs. CRP was a prognostic factor affecting the outcomes of treatments.
참고문헌 (37)
- Kawakita D, "Trends in the incidence of head and neck cancer by subsite between 1993and 2015 in Japan", Cancer Med, 11(6), pp.1553~1560 (2022)
- Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048):A randomised, open-label, phase 3 study", Lancet, 394(10212), pp.1915~1928 (2019)
- Al-Sarraf M, "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : Phase III randomized Intergroup study 0099", J Clin Oncol, 16(4), pp.1310~1317 (1998)
- Denis F, "Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma", J Clin Oncol, 22(1), pp.69~76 (2004)
- Licitra L, "Squamous cell carcinoma of the head and neck:ESMO clinical recommendations for diagnosis, treatment and follow-up", Ann Oncol, 20(Suppl 4), pp.121~122 (2009)
- Blanchard P, "Meta-analysis of chemotherapy in head and neck cancer(MACH-NC) : A comprehensive analysis by tumour site", Radiother Oncol, 100(1), pp.33~40 (2011)
- Straub JM, "Radiation-induced fibrosis : Mechanisms and implications for therapy", J Cancer Res Clin Oncol, 141(11), pp.1985~1994 (2015)
- Rana L, "Volumetric CT perfusion assessment of treatment response in head and neck squamous cell carcinoma : Comparison of CT perfusion parameters before and after chemoradiation therapy", Eur J Radiol Open, 2, pp.46~54 (2015)
- de Bree R, "Response assessment after induction chemotherapy for head and neck squamous cell carcinoma : From physical examination to modern imaging techniques and beyond", Head Neck, 39(11), pp.2329~2349 (2017)
- Chawla S, "Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck", AJR Am J Roentgenol, 200(1), pp.35~43 (2013)
- Goel R, "Clinical practice in PET", CT for the management of head and neck squamous cell cancer, 2017, pp.209(2), 289~303
- Farwell MD, "PET", CT imaging in cancer : Current applications and future directions, 2014, pp.120(22), 3433~3445
- Lee JC, "F-18FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma", Oral Oncol, 43(7), pp.686~692 (2007)
- 김기원, "FDG-PET", CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer, 2011, pp.29(4), 243~251[DOI]
- Paidpally V, "FDG-PET", CT imaging biomarkers in head and neck squamous cell carcinoma, 2012, pp.4(6), 633~647
- Kim R, "Predictive and prognostic value of PET", CT imaging postchemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma : A retrospective study, 2016, pp.16, 116~
- Pignon JP, "Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma : Three meta-analyses of updated individual data", Lancet, 355(9208), pp.949~955 (2000)
- Forastiere AA, "Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer", N Engl J Med, 349(22), pp.2091~2098 (2003)
- Lefebvre JL, "Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy", J Natl Cancer Inst, 101(3), pp.142~152 (2009)
- Johnson DE, "Head and neck squamous cell carcinoma", Nat Rev Dis Primers, 6(1), pp.92~ (2020)
- Brana I, "Locally advanced head and neck squamous cell cancer : Treatment choice based on risk factors and optimizing drug prescription", Ann Oncol, 23(Suppl 10), pp.x178~x185 (2012)
- Bellairs JA, "Tumor DNA : An emerging biomarker in head and neck cancer", Cancer Metastasis Rev, 36(3), pp.515~523 (2017)
- Hilke FJ, "Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy", Radiother Oncol, 151, pp.182~189 (2020)
- Verma T, "Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma", Indian J Pathol Microbiol, 63(4), pp.521~526 (2020)
- Mutschelknaus L, "Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells", Sci Rep, 7(1), pp.12423~ (2017)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", J Natl Cancer Inst, 92(3), pp.205~216 (2000)
- Eisenhauer EA, "New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)", Eur J Cancer, 45(2), pp.228~247 (2009)
- Wahl RL, "From RECIST to PERCIST : Evolving considerations for PET response criteria in solid tumors", J Nucl Med, 50(Suppl 1), pp.122S~150S (2009)
- Kishikawa T, "Response evaluation criteria in solid tumors(RECIST)and PET response criteria in solid tumors(PERCIST)for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma", Head Neck, 43(4), pp.1184~1193 (2021)
- Pfister DG, "Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 18(7), pp.873~898 (2020)
- Ong SC, "Clinical utility of 18F-FDG PET", CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer, 2008, pp.49(4), 532~540
- Vanderhoek M, "Impact of the definition of peak standardized uptake value on quantification of treatment response", J Nucl Med, 53(1), pp.4~11 (2012)
- Porceddu SV, "Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy", Head Neck, 33(12), pp.1675~1682 (2011)
- Marcus C, "Head and neck PET", CT: Therapy response interpretation criteria (Hopkins criteria)-interreader reliability, accuracy, and survival outcomes, 2014, pp.55(9), 1411~1416
- Koksel Y, "Utility of Likert scale(Deauville criteria)in assessment of chemoradiotherapy response of primary oropharyngeal squamous cell cancer site", Clin Imaging, 55, pp.89~94 (2019)
- Aiken AH, "ACR neck imaging reporting and data systems(NIRADS) : A white paper of the ACR NI-RADS committee", J Am Coll Radiol, 15(8), pp.1097~1108 (2018)
- Zhong J, "Post-treatment FDG PET-CT in head and neck carcinoma : Comparative analysis of 4 qualitative interpretative criteria in a large patient cohort", Sci Rep, 10(1), pp.4086~ (2020)